June 24, 2021 12:57 PM EDTUpdated 01:07 PM
Manufacturing

Emer­gen­t's bad year con­tin­ues with House over­sight com­mit­tee de­mand­ing doc­u­ments tied to vac­cine screwup

Josh Sullivan

In the lat­est seg­ment of the Emer­gent BioSo­lu­tions saga, US Rep. Car­olyn Mal­oney (D-NY) and Rep. James Clyburn (D-SC) have sent let­ters to ex­ec­u­tives with …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

Mer­ck’s long-await­ed obe­si­ty move is an oral GLP-1 from Chi­na

Ma­jor PBM re­forms fea­ture in Con­gress' year-end spend­ing bill

What Trump’s FTC picks mean for bio­phar­ma deal­mak­ing and PBMs

Up­dat­ed: Ver­tex’s non-opi­oid pill dis­ap­points in mid-stage chron­ic pain study

A service from the Financial Times